Kymera Therapeutics, Inc. – NASDAQ:KYMR
Founder-led company
Kymera Therapeutics stock price today
$42.57
+2.46
+6.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 1 minute
Kymera Therapeutics stock price monthly change
-5.18%
month
Kymera Therapeutics stock price quarterly change
-5.18%
quarter
Kymera Therapeutics stock price yearly change
+54.09%
year
Kymera Therapeutics key metrics
Market Cap | 2.58B |
Enterprise value | 1.76B |
P/E | -10.42 |
EV/Sales | 37.67 |
EV/EBITDA | -11.63 |
Price/Sales | 38.76 |
Price/Book | 3.70 |
PEG ratio | 0.27 |
EPS | -2.51 |
Revenue | 79.41M |
EBITDA | -160.19M |
Income | -154.59M |
Revenue Q/Q | 8.67% |
Revenue Y/Y | 70.15% |
Profit margin | -330.6% |
Oper. margin | -344.37% |
Gross margin | 0% |
EBIT margin | -344.37% |
EBITDA margin | -201.72% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKymera Therapeutics stock price history
Kymera Therapeutics stock forecast
Kymera Therapeutics financial statements
Average Price Target
$58.6
Potential upside: 37.65%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 16.51M | -38.79M | -234.96% |
|---|---|---|---|
| Sep 2023 | 4.72M | -52.86M | -1118.17% |
| Dec 2023 | 47.88M | -14.36M | -30.01% |
| Mar 2024 | 10.28M | -48.55M | -472.02% |
| Jun 2023 | 581945000 | 146.51M | 25.18% |
|---|---|---|---|
| Sep 2023 | 552378000 | 156.84M | 28.39% |
| Dec 2023 | 575759000 | 180.78M | 31.4% |
| Mar 2024 | 868251000 | 157.04M | 18.09% |
| Jun 2023 | -35.25M | 35.83M | 1.30M |
|---|---|---|---|
| Sep 2023 | -31.64M | 60.51M | -206K |
| Dec 2023 | 8.04M | 18.95M | 1.93M |
| Mar 2024 | -39.59M | -330.60M | 353.75M |
Kymera Therapeutics alternative data
| Aug 2023 | 174 |
|---|---|
| Sep 2023 | 181 |
| Oct 2023 | 181 |
| Nov 2023 | 181 |
| Dec 2023 | 192 |
| Jan 2024 | 192 |
| Feb 2024 | 192 |
| Mar 2024 | 187 |
| Apr 2024 | 187 |
| May 2024 | 187 |
| Jun 2024 | 186 |
| Jul 2024 | 186 |
Kymera Therapeutics other data
95.17%
-0.07%
of KYMR is owned by hedge funds
108
+11
49.27M
+81.43K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 979014 | 13295 |
| Feb 2024 | 0 | 51537 |
| Mar 2024 | 0 | 841535 |
| May 2024 | 0 | 2575 |
| Jun 2024 | 0 | 35440 |
| Jul 2024 | 0 | 493560 |
| Aug 2024 | 2952448 | 5000 |
| Sep 2024 | 0 | 13500 |
| Dec 2024 | 0 | 2500 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ESPOSITO PAMELA director | Stock Option (Right to Buy) | 2,500 | $29.55 | $73,875 | ||
Option | ESPOSITO PAMELA director | Common Stock | 2,500 | $29.55 | $73,875 | ||
Sale | ESPOSITO PAMELA director | Common Stock | 2,500 | $49 | $122,500 | ||
Option | ESPOSITO PAMELA director | Stock Option (Right to Buy) | 8,500 | $29.55 | $251,175 | ||
Option | ESPOSITO PAMELA director | Common Stock | 5,000 | $14.18 | $70,900 | ||
Option | ESPOSITO PAMELA director | Common Stock | 8,500 | $29.55 | $251,175 | ||
Sale | ESPOSITO PAMELA director | Common Stock | 6,350 | $47.75 | $303,187 | ||
Option | ESPOSITO PAMELA director | Stock Option (Right to Buy) | 5,000 | $14.18 | $70,900 | ||
Sale | ESPOSITO PAMELA director | Common Stock | 7,150 | $48.75 | $348,584 | ||
Option | ALBERS JEFFREY W. director | Stock Option (Right to Buy) | 5,000 | $10.34 | $51,700 |
| Patent |
|---|
Application Filling date: 15 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 15 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 15 Feb 2022 Issue date: 1 Sep 2022 |
Grant Utility: CRBN ligands and uses thereof Filling date: 21 Sep 2018 Issue date: 14 Jun 2022 |
Grant Utility: IRAK degraders and uses thereof Filling date: 2 Dec 2019 Issue date: 7 Jun 2022 |
Grant Utility: IRAK degraders and uses thereof Filling date: 16 Oct 2020 Issue date: 3 May 2022 |
Grant Filling date: 3 Jul 2019 Issue date: 5 Apr 2022 |
Application Filling date: 29 Jul 2021 Issue date: 24 Feb 2022 |
Application Filling date: 3 Jun 2021 Issue date: 23 Dec 2021 |
Application Filling date: 2 Dec 2019 Issue date: 21 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. (1979) Co-Founder, Pres, Chief Executive Officer & Director | $832,620 |
| Dr. Jared A. Gollob (1964) Chief Medical Officer | $577,210 |
Dr. Bruce L. Booth D.Phil., Ph.D. (1974) Co-Founder & Chairman | $26,530 |
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
Kymera Therapeutics - Need More Developments Before Making This A Buy
Kymera: More Data Needed
Kymera: Data Derisks Platform, But I Will Wait For More
Kymera: Upcoming Trial Data Will Make Or Break The Company
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
Kymera: Targeting The Protein Degradation Space
-
What's the price of Kymera Therapeutics stock today?
One share of Kymera Therapeutics stock can currently be purchased for approximately $42.57.
-
When is Kymera Therapeutics's next earnings date?
Unfortunately, Kymera Therapeutics's (KYMR) next earnings date is currently unknown.
-
Does Kymera Therapeutics pay dividends?
No, Kymera Therapeutics does not pay dividends.
-
How much money does Kymera Therapeutics make?
Kymera Therapeutics has a market capitalization of 2.58B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 67.84% to 78.59M US dollars.
-
What is Kymera Therapeutics's stock symbol?
Kymera Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KYMR".
-
What is Kymera Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kymera Therapeutics?
Shares of Kymera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kymera Therapeutics's key executives?
Kymera Therapeutics's management team includes the following people:
- Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 46, pay: $832,620)
- Dr. Jared A. Gollob Chief Medical Officer(age: 61, pay: $577,210)
- Dr. Bruce L. Booth D.Phil., Ph.D. Co-Founder & Chairman(age: 51, pay: $26,530)
-
Is Kymera Therapeutics founder-led company?
Yes, Kymera Therapeutics is a company led by its founders Dr. Nello Mainolfi M.D., Ph.D. and Dr. Bruce L. Booth D.Phil., Ph.D..
-
How many employees does Kymera Therapeutics have?
As Jul 2024, Kymera Therapeutics employs 186 workers, which is 1% less then previous quarter.
-
When Kymera Therapeutics went public?
Kymera Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 21 Aug 2020.
-
What is Kymera Therapeutics's official website?
The official website for Kymera Therapeutics is kymeratx.com.
-
Where are Kymera Therapeutics's headquarters?
Kymera Therapeutics is headquartered at 200 Arsenal Yards Boulevard, Watertown, MA.
-
How can i contact Kymera Therapeutics?
Kymera Therapeutics's mailing address is 200 Arsenal Yards Boulevard, Watertown, MA and company can be reached via phone at 857 285 5300.
-
What is Kymera Therapeutics stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Kymera Therapeutics in the last 12 months, the avarage price target is $58.6. The average price target represents a 37.65% change from the last price of $42.57.
Kymera Therapeutics company profile:
Kymera Therapeutics, Inc.
kymeratx.comExchange:
NASDAQ
Full time employees:
184
Industry:
Biotechnology
Sector:
Healthcare
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
200 Arsenal Yards Boulevard
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001815442
ISIN: US5015751044
CUSIP: 501575104
